An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

Trial Profile

An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs GDC 0425 (Primary) ; Gemcitabine
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 04 Nov 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 09 Jun 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 12 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2014 to 1 May 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top